Drug Profile
PXS 25
Alternative Names: PXS25Latest Information Update: 13 Dec 2023
Price :
$50
*
At a glance
- Originator Pharmaxis
- Developer Syntara Limited
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fibrosis